ANGPTL3 inhibitors for reduction of cardiovascular disease risk
Rosenson, Robert
( MT SINAI SCHOOL MEDICINE
, New York
, New York
, United States
)
Author Disclosures:
Robert Rosenson:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Amgen:Active (exists now)
; Consultant:Intercept Pharmaceuticals:Past (completed)
; Consultant:Eli Lilly:Active (exists now)
; Consultant:Editas Medicine:Past (completed)
; Consultant:CRISPER Therapeutics:Past (completed)
; Consultant:Arrowhead:Active (exists now)
; Consultant:Amgen:Active (exists now)
; Research Funding (PI or named investigator):Shanghai Argo Biopharmaceutical Co.:Active (exists now)
; Research Funding (PI or named investigator):89Bio:Active (exists now)
; Research Funding (PI or named investigator):Novo Nordisk:Past (completed)
; Research Funding (PI or named investigator):Novartis:Active (exists now)
; Research Funding (PI or named investigator):NIH:Active (exists now)
; Research Funding (PI or named investigator):Merck:Active (exists now)
; Research Funding (PI or named investigator):Eli Lilly:Active (exists now)
; Research Funding (PI or named investigator):Arrowhead:Active (exists now)